BofA analyst Koji Ikeda raised the firm’s price target on Enfusion to $9 from $8 and keeps an Underperform rating on the shares. Enfusion’s Q4 results were “good,” but sustained outperformance is “uncertain” and next week’s investor day is “key,” the analyst tells investors in a post-earnings note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ENFN: